An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Study Summary

A clinical trial of AAV2/5 vector for patients with Defects in RPE65

Interventions

Study Locations

Facility	City	State	Country
Kellogg Eye Centre, University of Michigan	Ann Arbor	Michigan	United States
Moorfields Eye Hospital NHS Foundation Trust	London		United Kingdom

Official Trial Information

View on ClinicalTrials.gov